Australien - engelsk - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1.5 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; magnesium stearate; maize starch; hypromellose; carbomer 941 - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.75 mg - tablet, modified release - excipient ingredients: maize starch; colloidal anhydrous silica; hypromellose; carbomer 941; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.375 mg - tablet, modified release - excipient ingredients: maize starch; hypromellose; magnesium stearate; colloidal anhydrous silica; carbomer 941 - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 3.75 mg - tablet, modified release - excipient ingredients: carbomer 941; colloidal anhydrous silica; maize starch; hypromellose; magnesium stearate - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 2.25 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; maize starch; colloidal anhydrous silica; carbomer 941 - for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.25 mg - tablet - excipient ingredients: crospovidone; colloidal anhydrous silica; mannitol; sodium citrate; pregelatinised maize starch; hyprolose; magnesium stearate - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - pramipexole dihydrochloride monohydrate, quantity: 1 mg - tablet - excipient ingredients: hyprolose; colloidal anhydrous silica; crospovidone; magnesium stearate; pregelatinised maize starch; sodium citrate; mannitol - simpral is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. it is also indicated for the symptomatic treatment of primary restless legs syndrome.

USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical, inc. - pramipexole dihydrochloride (unii: 3d867np06j) (pramipexole - unii:83619peu5t) - pramipexole dihydrochloride 0.375 mg - pramipexole dihydrochloride extended-release tablets are indicated for the treatment of parkinson's disease. none. risk summary there are no adequate data on the developmental risk associated with the use of pramipexole dihydrochloride extended-release tablets in pregnant women. no adverse developmental effects were observed in animal studies in which pramipexole was administered to rabbits during pregnancy. effects on embryofetal development could not be adequately assessed in pregnant rats; however, postnatal growth was inhibited at clinically relevant exposures [see data] . in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data oral administration of pramipexole (0.1, 0.5, or 1.5 mg/kg/day) to pregnant rats during the period of organogenesis resulted in a high inciden

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - pramipexole dihydrochloride monohydrate, quantity: 0.125 mg - tablet, uncoated - excipient ingredients: povidone; maize starch; mannitol; colloidal anhydrous silica; magnesium stearate - sifrol is indicated for the treatment of signs and symptoms of idiopathic parkinson's disease. it may be used as monotherapy or in combination with levodopa. sifrol is indicated for the symptomatic treatment of primary restless legs syndrome.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - pramipexole dihydrochloride monohydrate -